Index RUT
P/E -
EPS (ttm) -0.74
Insider Own 1.51%
Shs Outstand 192.74M
Perf Week -11.99%
Market Cap 247.67M
Forward P/E -
EPS next Y -0.90
Insider Trans -1.31%
Shs Float 189.83M
Perf Month -23.51%
Income -91.17M
PEG -
EPS next Q -0.45
Inst Own 67.23%
Short Float 17.93%
Perf Quarter -8.21%
Sales 21.73M
P/S 11.40
EPS this Y 10.66%
Inst Trans 7.50%
Short Ratio 3.43
Perf Half Y -58.01%
Book/sh 2.08
P/B 0.62
EPS next Y 45.82%
ROA -16.08%
Short Interest 34.04M
Perf Year -70.25%
Cash/sh 0.95
P/C 1.35
EPS next 5Y 45.80%
ROE -47.81%
52W Range 0.88 - 5.53
Perf YTD -6.88%
Dividend Est. -
P/FCF -
EPS past 5Y 15.14%
ROI -20.06%
52W High -76.76%
Beta 0.77
Dividend TTM -
Quick Ratio 1.42
Sales past 5Y -29.98%
Gross Margin -15.86%
52W Low 46.19%
ATR (14) 0.16
Dividend Ex-Date -
Current Ratio 1.55
EPS Y/Y TTM 87.79%
Oper. Margin -1523.91%
RSI (14) 46.45
Volatility 11.38% 12.49%
Employees 323
Debt/Eq 1.36
Sales Y/Y TTM 322.60%
Profit Margin -419.62%
Recom 2.79
Target Price 5.22
Option/Short Yes / Yes
LT Debt/Eq 1.04
EPS Q/Q 29.93%
Payout -
Rel Volume 0.52
Prev Close 1.37
Sales Surprise -53.53%
EPS Surprise -2.77%
Sales Q/Q 17353.52%
Earnings Mar 26 BMO
Avg Volume 9.91M
Price 1.28
SMA20 -8.69%
SMA50 2.58%
SMA200 -52.34%
Trades
Volume 4,740,640
Change -5.86%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-11-23 Downgrade
HSBC Securities
Hold → Reduce
Dec-08-23 Upgrade
Morgan Stanley
Underweight → Equal-Weight
$3 → $7
Oct-17-23 Initiated
Cantor Fitzgerald
Neutral
Sep-06-23 Initiated
HSBC Securities
Buy
$4.21
Jul-19-23 Upgrade
BofA Securities
Neutral → Buy
$6 → $10
Jun-01-23 Upgrade
Barclays
Equal Weight → Overweight
$7 → $8
Apr-28-23 Initiated
JP Morgan
Overweight
$7
Mar-07-23 Initiated
Robert W. Baird
Outperform
$10
Aug-05-22 Upgrade
Barclays
Underweight → Equal Weight
Aug-02-22 Upgrade
Raymond James
Mkt Perform → Outperform
$8
Apr-06-22 Downgrade
Cowen
Outperform → Market Perform
Mar-07-22 Downgrade
Barclays
Equal Weight → Underweight
$4
Nov-08-21 Reiterated
Wells Fargo
Equal Weight
$25 → $16
Nov-08-21 Reiterated
Wedbush
Neutral
$22 → $11
Nov-08-21 Reiterated
RBC Capital Mkts
Sector Perform
$26 → $14
Nov-08-21 Reiterated
Canaccord Genuity
Hold
$20 → $15
Nov-08-21 Reiterated
Barclays
Equal Weight
$20 → $13
Nov-08-21 Downgrade
Morgan Stanley
Equal-Weight → Underweight
$11
Nov-08-21 Downgrade
Goldman
Neutral → Sell
$23 → $10
Aug-10-21 Resumed
William Blair
Mkt Perform
Show Previous Ratings
Mar-27-24 11:37AM
10:00AM
Mar-26-24 07:01AM
Mar-25-24 04:05PM
Mar-19-24 07:44AM
06:05PM
Loading…
Mar-18-24 06:05PM
08:00AM
Mar-13-24 07:50AM
Mar-11-24 08:00AM
Mar-05-24 06:56PM
Jan-27-24 07:28AM
05:27AM
Jan-10-24 06:55AM
Jan-08-24 08:00AM
Jan-04-24 03:32PM
(The Wall Street Journal) +5.84%
07:15AM
Loading…
Jan-03-24 07:15AM
Jan-02-24 08:00AM
Dec-26-23 08:00AM
Dec-24-23 07:39AM
Dec-23-23 07:30AM
Dec-22-23 08:45AM
Dec-20-23 02:23PM
01:54PM
Dec-19-23 09:41PM
Dec-18-23 04:01PM
Dec-15-23 11:14AM
Dec-11-23 05:43AM
Dec-10-23 12:02PM
Dec-09-23 11:31AM
Dec-08-23 01:45PM
(The Wall Street Journal) -40.54%
01:01PM
Loading…
01:01PM
12:35PM
Dec-07-23 11:30AM
08:45AM
Dec-01-23 07:41AM
Nov-29-23 02:28PM
Nov-26-23 04:44PM
Nov-24-23 07:00AM
(The Wall Street Journal)
Nov-08-23 03:39PM
Nov-07-23 05:18PM
08:00AM
07:46AM
07:27AM
(Associated Press Finance)
07:00AM
Nov-04-23 08:45AM
Nov-02-23 09:37AM
Oct-30-23 08:00AM
Oct-24-23 08:00AM
Oct-17-23 09:47AM
Sep-29-23 09:00AM
Sep-20-23 07:21AM
Sep-12-23 07:00AM
05:14AM
Sep-07-23 11:30AM
Sep-05-23 04:05PM
Aug-29-23 05:25AM
Aug-28-23 08:30AM
Aug-24-23 10:15AM
Aug-16-23 07:00AM
Aug-08-23 08:25AM
07:18AM
07:00AM
07:00AM
Aug-05-23 09:40AM
Jul-27-23 11:19AM
Jul-25-23 08:00AM
Jul-22-23 06:14AM
Jul-20-23 01:14AM
Jul-19-23 12:36PM
Jun-30-23 10:15AM
Jun-29-23 09:53AM
07:45AM
Jun-21-23 07:00AM
Jun-15-23 10:00AM
Jun-08-23 11:30AM
Jun-01-23 02:09AM
May-10-23 07:57AM
May-09-23 07:10AM
07:00AM
Apr-27-23 04:05PM
Apr-24-23 03:49PM
07:30AM
Apr-13-23 02:17PM
Apr-06-23 10:15AM
08:00AM
06:30AM
Apr-02-23 09:15AM
Mar-30-23 01:54PM
Mar-29-23 08:15AM
07:00AM
Feb-24-23 10:00AM
Feb-08-23 08:05AM
Feb-03-23 05:00AM
(American City Business Journals)
Jan-30-23 09:12AM
Jan-24-23 08:58AM
Jan-22-23 09:00AM
Jan-18-23 08:00PM
09:12AM
06:43AM
Jan-09-23 07:00AM
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Obenshain Andrew President and CEO Mar 04 '24 Sale 1.53 6,095 9,311 279,998 Mar 05 05:40 PM Klima Thomas J See Remarks Mar 04 '24 Sale 1.53 4,573 6,986 124,840 Mar 05 05:39 PM Colvin Richard A Chief Medical Officer Mar 01 '24 Sale 1.53 6,770 10,342 118,368 Mar 05 05:40 PM Vittiglio Joseph Chief Business & Legal Officer Feb 05 '24 Sale 0.90 5,217 4,708 44,783 Feb 06 04:07 PM Klima Thomas J See Remarks Feb 05 '24 Sale 0.90 2,714 2,449 129,413 Feb 06 04:07 PM Obenshain Andrew President and CEO Feb 05 '24 Sale 0.90 1,879 1,696 286,093 Feb 06 04:07 PM Obenshain Andrew President and CEO Jan 05 '24 Sale 1.43 3,162 4,520 287,972 Jan 09 04:05 PM Colvin Richard A Chief Medical Officer Jan 05 '24 Sale 1.42 597 845 125,138 Jan 09 04:05 PM Krawtschuk Christopher Chief Financial Officer Dec 06 '23 Sale 4.52 4,526 20,437 45,474 Dec 08 04:42 PM Obenshain Andrew President and CEO Nov 03 '23 Sale 3.17 807 2,555 291,134 Nov 03 04:10 PM Colvin Richard A Chief Medical Officer Nov 02 '23 Sale 2.98 2,343 6,975 125,735 Nov 03 04:10 PM Klima Thomas J See Remarks Sep 05 '23 Sale 3.79 922 3,493 132,127 Sep 06 04:30 PM Obenshain Andrew President and CEO Aug 10 '23 Sale 3.54 16,929 59,956 291,941 Aug 10 05:00 PM Klima Thomas J See Remarks Jun 02 '23 Sale 3.50 4,130 14,451 133,049 Jun 06 04:06 PM
Index -
P/E -
EPS (ttm) -1.14
Insider Own 1.04%
Shs Outstand 181.36M
Perf Week 12.74%
Market Cap 12.69B
Forward P/E 562.98
EPS next Y 0.12
Insider Trans -5.72%
Shs Float 179.64M
Perf Month 24.13%
Income -204.15M
PEG -
EPS next Q -0.48
Inst Own 90.12%
Short Float 3.63%
Perf Quarter -7.64%
Sales 2.50B
P/S 5.08
EPS this Y 21.81%
Inst Trans -1.74%
Short Ratio 3.35
Perf Half Y 3.62%
Book/sh 17.34
P/B 4.03
EPS next Y 114.05%
ROA -3.00%
Short Interest 6.52M
Perf Year 5.45%
Cash/sh 4.28
P/C 16.32
EPS next 5Y -
ROE -6.60%
52W Range 56.05 - 100.77
Perf YTD -5.52%
Dividend Est. -
P/FCF 397.40
EPS past 5Y 4.59%
ROI -3.63%
52W High -30.63%
Beta 1.24
Dividend TTM -
Quick Ratio 2.07
Sales past 5Y 43.88%
Gross Margin 70.14%
52W Low 24.71%
ATR (14) 2.68
Dividend Ex-Date -
Current Ratio 2.32
EPS Y/Y TTM 67.92%
Oper. Margin -12.20%
RSI (14) 70.24
Volatility 3.75% 4.28%
Employees 6600
Debt/Eq 0.82
Sales Y/Y TTM 19.93%
Profit Margin -8.17%
Recom 1.32
Target Price 89.78
Option/Short Yes / Yes
LT Debt/Eq 0.79
EPS Q/Q 61.80%
Payout -
Rel Volume 2.48
Prev Close 66.88
Sales Surprise 1.26%
EPS Surprise 36.16%
Sales Q/Q 16.98%
Earnings Feb 21 AMC
Avg Volume 1.95M
Price 69.90
SMA20 15.10%
SMA50 13.13%
SMA200 -4.06%
Trades
Volume 4,406,406
Change 4.52%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-02-24 Upgrade
The Benchmark Company
Hold → Buy
$91
Dec-14-23 Initiated
Guggenheim
Buy
$90
Dec-13-23 Initiated
Wolfe Research
Outperform
$95
Oct-10-23 Upgrade
Piper Sandler
Neutral → Overweight
$90
Sep-28-23 Initiated
Bernstein
Outperform
$83
Aug-02-23 Downgrade
The Benchmark Company
Buy → Hold
May-10-23 Upgrade
Craig Hallum
Hold → Buy
$55 → $85
May-05-23 Initiated
UBS
Neutral
$73
Mar-09-23 Upgrade
Citigroup
Neutral → Buy
$70 → $90
Feb-10-23 Downgrade
Credit Suisse
Outperform → Neutral
$50 → $70
Jan-18-23 Downgrade
Raymond James
Outperform → Mkt Perform
Oct-19-22 Downgrade
Craig Hallum
Buy → Hold
$60 → $35
Aug-25-22 Initiated
Credit Suisse
Outperform
$55
Jun-03-22 Initiated
Piper Sandler
Neutral
$50
Nov-03-21 Downgrade
Raymond James
Strong Buy → Outperform
$160 → $130
Jul-29-21 Reiterated
Stifel
Buy
$165 → $145
Jul-29-21 Reiterated
Oppenheimer
Outperform
$161 → $155
Jul-29-21 Reiterated
Canaccord Genuity
Buy
$185 → $160
Jul-29-21 Reiterated
BTIG Research
Buy
$155 → $145
Jun-15-21 Initiated
Raymond James
Strong Buy
$160
Show Previous Ratings
Today 06:00AM
Mar-27-24 08:05AM
Mar-25-24 09:55AM
Mar-22-24 11:30AM
Mar-18-24 08:19AM
04:30AM
Loading…
04:30AM
Mar-14-24 04:16PM
(Investor's Business Daily)
Mar-13-24 05:03PM
Mar-11-24 12:59AM
Mar-08-24 09:55AM
Mar-07-24 07:59AM
Mar-04-24 11:52PM
03:49PM
10:38AM
Mar-03-24 10:32AM
06:00AM
Loading…
Feb-26-24 06:00AM
Feb-23-24 12:01PM
Feb-22-24 11:08AM
10:30AM
(Thomson Reuters StreetEvents)
10:22AM
01:30AM
12:06AM
Feb-21-24 06:20PM
05:41PM
(Associated Press Finance)
05:12PM
04:05PM
Feb-20-24 02:39AM
Feb-15-24 07:47AM
Feb-14-24 10:00AM
Feb-13-24 08:12PM
05:06PM
Loading…
Feb-10-24 05:06PM
Feb-07-24 09:00AM
Feb-01-24 06:00AM
Jan-28-24 09:25AM
Jan-22-24 08:00AM
Jan-18-24 05:04AM
Jan-13-24 02:05PM
Jan-08-24 02:48PM
Jan-07-24 04:30PM
Jan-02-24 06:00AM
Dec-21-23 09:43AM
Dec-20-23 01:49PM
Dec-17-23 05:43AM
Dec-14-23 04:02AM
Dec-13-23 12:52PM
08:45AM
Dec-07-23 08:05AM
Dec-05-23 09:11AM
Dec-04-23 12:13PM
Dec-01-23 11:32AM
05:26AM
Nov-30-23 04:05PM
Nov-25-23 09:45AM
Nov-23-23 12:02PM
Nov-20-23 03:06PM
09:55AM
07:30AM
Nov-17-23 08:04PM
(Morningstar Research) +8.39%
07:10AM
Nov-14-23 05:20AM
Nov-10-23 07:00AM
Nov-09-23 08:10PM
(Morningstar Research) -5.09%
Nov-06-23 09:35AM
Nov-03-23 08:09PM
(Morningstar Research) +7.30%
Nov-02-23 07:23PM
04:02PM
(Investor's Business Daily)
11:03AM
09:40AM
(Thomson Reuters StreetEvents)
01:14AM
12:30AM
Nov-01-23 06:06PM
04:05PM
06:00AM
Oct-31-23 05:20PM
11:25AM
Oct-30-23 10:20PM
Oct-27-23 08:11PM
Oct-26-23 10:02AM
Oct-25-23 10:02AM
Oct-23-23 08:52PM
Oct-22-23 03:00PM
Oct-20-23 06:08PM
Oct-19-23 02:28PM
09:49AM
Oct-16-23 10:08AM
Oct-12-23 06:00AM
Oct-11-23 08:23AM
Oct-10-23 12:18PM
09:32AM
01:16AM
Oct-09-23 06:00AM
05:58AM
Oct-08-23 07:30AM
Oct-03-23 11:11AM
09:40AM
Oct-02-23 10:45AM
Sep-29-23 09:01PM
(American City Business Journals)
Sep-27-23 09:45AM
Sep-22-23 11:28AM
Sep-12-23 08:35AM
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Conroy Kevin T President and CEO Mar 01 '24 Sale 59.32 8,271 490,636 1,299,496 Mar 04 08:38 PM LEVANGIE DANIEL J Director Mar 01 '24 Sale 57.50 5,000 287,500 22,975 Mar 04 08:42 PM Cunningham Everett Chief Commercial Officer Mar 01 '24 Sale 59.32 2,412 143,080 46,179 Mar 04 08:38 PM Elliott Jeffrey Thomas Chief Financial Officer Mar 01 '24 Sale 59.32 2,412 143,080 10,933 Mar 04 08:40 PM Baranick Brian Gen. Mgr., Precision Oncology Mar 01 '24 Sale 59.32 2,323 137,800 14,095 Mar 04 08:36 PM ORVILLE JACOB A General Manager, Screening Mar 01 '24 Sale 59.32 2,154 127,775 14,324 Mar 04 08:42 PM Doyle James Edward Director Mar 01 '24 Sale 57.50 2,000 115,000 50,110 Mar 04 08:39 PM Condella Sarah EVP, Human Resources Mar 01 '24 Sale 59.32 1,724 102,268 75,787 Mar 04 08:37 PM Herriott James General Counsel Mar 01 '24 Sale 59.32 862 51,134 9,125 Mar 04 08:41 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 29 '24 Option Exercise 0.00 5,291 0 13,345 Mar 04 08:40 PM Cunningham Everett Chief Commercial Officer Feb 29 '24 Option Exercise 0.00 5,291 0 48,591 Mar 04 08:38 PM Conroy Kevin T President and CEO Feb 29 '24 Option Exercise 0.00 18,143 0 1,307,767 Mar 04 08:38 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 29 '24 Option Exercise 0.00 4,724 0 16,418 Mar 04 08:36 PM Herriott James General Counsel Feb 29 '24 Option Exercise 0.00 1,890 0 9,987 Mar 04 08:41 PM ORVILLE JACOB A General Manager, Screening Feb 29 '24 Option Exercise 0.00 4,724 0 16,478 Mar 04 08:42 PM Condella Sarah EVP, Human Resources Feb 29 '24 Option Exercise 0.00 3,779 0 77,511 Mar 04 08:37 PM Conroy Kevin T President and CEO Feb 27 '24 Sale 56.89 6,263 356,302 1,289,624 Feb 28 07:35 PM Cunningham Everett Chief Commercial Officer Feb 27 '24 Sale 56.89 3,648 207,535 43,300 Feb 28 07:37 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 27 '24 Sale 56.89 2,710 154,172 8,054 Feb 28 07:36 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 27 '24 Sale 56.89 2,027 115,316 11,694 Feb 28 07:34 PM Condella Sarah EVP, Human Resources Feb 27 '24 Sale 56.89 1,880 106,953 73,732 Feb 28 07:35 PM ORVILLE JACOB A General Manager, Screening Feb 27 '24 Sale 56.89 1,879 106,896 11,754 Feb 28 07:38 PM Herriott James General Counsel Feb 27 '24 Sale 56.89 784 44,602 8,097 Feb 28 07:38 PM Cunningham Everett Chief Commercial Officer Feb 26 '24 Option Exercise 0.00 7,678 0 46,948 Feb 28 07:37 PM ORVILLE JACOB A General Manager, Screening Feb 26 '24 Option Exercise 0.00 3,954 0 13,633 Feb 28 07:38 PM Herriott James General Counsel Feb 26 '24 Option Exercise 0.00 1,648 0 8,881 Feb 28 07:38 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 26 '24 Option Exercise 0.00 5,701 0 10,764 Feb 28 07:36 PM Condella Sarah EVP, Human Resources Feb 26 '24 Option Exercise 0.00 3,954 0 75,612 Feb 28 07:35 PM Conroy Kevin T President and CEO Feb 26 '24 Option Exercise 0.00 13,181 0 1,295,887 Feb 28 07:35 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 26 '24 Option Exercise 0.00 3,954 0 13,721 Feb 28 07:34 PM Conroy Kevin T President and CEO Feb 23 '24 Option Exercise 13.96 102,837 1,435,605 1,344,266 Feb 26 05:00 PM Condella Sarah EVP, Human Resources Feb 23 '24 Sale 59.72 1,021 60,974 71,658 Feb 26 05:00 PM Conroy Kevin T President and CEO Feb 22 '24 Sale 59.78 11,565 691,356 1,241,429 Feb 23 07:59 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 22 '24 Sale 59.78 1,351 80,763 5,063 Feb 23 08:01 PM Cunningham Everett Chief Commercial Officer Feb 22 '24 Sale 59.78 1,350 80,703 39,270 Feb 23 08:00 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 22 '24 Sale 59.78 1,093 65,340 9,767 Feb 23 07:57 PM Condella Sarah EVP, Human Resources Feb 22 '24 Sale 59.78 1,013 60,557 72,679 Feb 23 07:57 PM ORVILLE JACOB A General Manager, Screening Feb 22 '24 Sale 59.78 1,013 60,557 9,679 Feb 23 08:03 PM COWARD D SCOTT Director Feb 22 '24 Sale 59.78 663 39,634 44,493 Feb 23 07:59 PM Herriott James General Counsel Feb 22 '24 Sale 59.78 291 17,396 7,233 Feb 23 08:02 PM Conroy Kevin T President and CEO Feb 21 '24 Sale 61.50 4,975 305,962 1,229,756 Feb 22 07:37 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 21 '24 Sale 61.50 1,493 91,820 3,703 Feb 22 07:38 PM Condella Sarah EVP, Human Resources Feb 21 '24 Sale 61.50 1,079 66,358 71,658 Feb 22 07:36 PM ORVILLE JACOB A General Manager, Screening Feb 21 '24 Sale 61.50 1,078 66,297 8,658 Feb 22 07:40 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 21 '24 Sale 61.50 895 55,042 8,826 Feb 22 07:36 PM COWARD D SCOTT Director Feb 21 '24 Sale 61.50 706 43,419 43,122 Feb 22 07:38 PM Herriott James General Counsel Feb 21 '24 Sale 61.50 415 25,522 6,943 Feb 22 07:39 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 20 '24 Option Exercise 0.00 3,112 0 5,196 Feb 22 07:38 PM Conroy Kevin T President and CEO Feb 20 '24 Option Exercise 0.00 10,374 0 1,234,731 Feb 22 07:37 PM COWARD D SCOTT Director Feb 20 '24 Option Exercise 0.00 2,248 0 43,828 Feb 22 07:38 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 20 '24 Option Exercise 0.00 1,729 0 9,721 Feb 22 07:36 PM Condella Sarah EVP, Human Resources Feb 20 '24 Option Exercise 0.00 2,248 0 72,737 Feb 22 07:36 PM Herriott James General Counsel Feb 20 '24 Option Exercise 0.00 864 0 7,358 Feb 22 07:39 PM ORVILLE JACOB A General Manager, Screening Feb 20 '24 Option Exercise 0.00 2,248 0 9,736 Feb 22 07:40 PM Conroy Kevin T President and CEO Feb 15 '24 Sale 61.43 14,791 908,611 1,224,357 Feb 16 06:22 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 15 '24 Sale 61.43 1,888 115,980 2,084 Feb 16 06:24 PM COWARD D SCOTT Director Feb 15 '24 Sale 61.43 1,376 84,528 41,580 Feb 16 06:23 PM ORVILLE JACOB A General Manager, Screening Feb 15 '24 Sale 61.43 966 59,341 7,488 Feb 16 06:26 PM Condella Sarah EVP, Human Resources Feb 15 '24 Sale 61.43 965 59,280 70,489 Feb 16 06:21 PM Herriott James General Counsel Feb 15 '24 Sale 61.43 421 25,862 6,494 Feb 16 06:25 PM Conroy Kevin T President and CEO Feb 14 '24 Option Exercise 0.00 31,133 0 1,239,148 Feb 16 06:22 PM ORVILLE JACOB A General Manager, Screening Feb 14 '24 Option Exercise 0.00 2,031 0 8,454 Feb 16 06:26 PM Herriott James General Counsel Feb 14 '24 Option Exercise 0.00 883 0 6,915 Feb 16 06:25 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 14 '24 Option Exercise 0.00 3,972 0 3,972 Feb 16 06:24 PM COWARD D SCOTT Director Feb 14 '24 Option Exercise 0.00 3,972 0 42,956 Feb 16 06:23 PM Condella Sarah EVP, Human Resources Feb 14 '24 Option Exercise 0.00 2,031 0 71,454 Feb 16 06:21 PM Condella Sarah EVP, Human Resources Jan 02 '24 Sale 73.50 2,000 147,000 69,423 Jan 04 05:19 PM Baranick Brian Gen. Mgr., Precision Oncology Jan 02 '24 Sale 73.50 879 64,606 7,992 Jan 04 05:17 PM Condella Sarah EVP, Human Resources Dec 14 '23 Sale 70.00 2,000 140,000 71,423 Dec 18 07:49 PM Cunningham Everett Chief Commercial Officer Oct 12 '23 Sale 66.49 13,007 864,835 37,909 Oct 13 07:59 PM Cunningham Everett Chief Commercial Officer Oct 11 '23 Option Exercise 0.00 27,504 0 50,916 Oct 13 07:59 PM Condella Sarah EVP, Human Resources Sep 01 '23 Sale 84.36 4,500 379,620 75,814 Sep 06 04:04 PM Elliott Jeffrey Thomas Chief Financial Officer Aug 21 '23 Sale 82.92 30,210 2,505,013 0 Aug 23 04:08 PM Baranick Brian Gen. Mgr., Precision Oncology Aug 07 '23 Sale 85.04 1,350 114,804 8,871 Aug 08 04:09 PM Baranick Brian Gen. Mgr., Precision Oncology Aug 04 '23 Option Exercise 0.00 2,712 0 10,221 Aug 08 04:09 PM Doyle James Edward Director Jul 27 '23 Sale 97.42 2,000 194,840 52,110 Jul 28 04:06 PM Herriott James General Counsel Jul 19 '23 Sale 100.00 1,300 130,000 5,964 Jul 21 04:04 PM Zanotti Katherine S Director Jun 09 '23 Sale 90.51 3,027 273,974 64,629 Jun 12 04:17 PM Doyle James Edward Director Jun 09 '23 Sale 90.51 1,402 126,895 54,110 Jun 12 04:29 PM Herriott James General Counsel Jun 08 '23 Sale 90.00 1,300 117,000 7,264 Jun 12 04:14 PM Doyle James Edward Director May 26 '23 Sale 80.62 2,000 161,240 51,913 May 31 04:13 PM Condella Sarah EVP, Human Resources May 10 '23 Sale 80.00 6,087 486,960 80,314 May 12 04:11 PM ORVILLE JACOB A General Manager, Screening May 10 '23 Sale 80.00 5,000 400,000 6,423 May 12 04:09 PM Herriott James General Counsel May 10 '23 Sale 79.85 1,300 103,805 8,564 May 12 04:07 PM Condella Sarah EVP, Human Resources May 01 '23 Sale 63.78 1,000 63,780 86,401 May 03 04:04 PM Condella Sarah EVP, Human Resources Apr 03 '23 Sale 67.19 1,000 67,190 86,692 Apr 05 04:10 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite